Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497027 · ClinicalTrials.gov registry record · NA
Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
A NA study, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT02497027 is a NA study that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 83 participants.
The verdict
NCT02497027, a NA study, has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).
Interventions
- OTHER pharmacogenetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497027
The ClinicalTrials.gov registry entry for NCT02497027 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pharmacogenetic testing is the first listed.
NCT02497027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497027 about?
NCT02497027 is a clinical study titled "Pharmacogenetic Testing in an Outpatient Population of Patients With Depression". This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified...
What is the current status of trial NCT02497027?
This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2015-02. Estimated completion is 2017-04-01.
What interventions are being tested in trial NCT02497027?
The interventions under investigation include: pharmacogenetic testing (OTHER).
Who is sponsoring clinical trial NCT02497027?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.